Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oligonucleotides - short DNA or RNA molecules - have great therapeutic application for a range of diseases. Yet, their potential has not been fully unleashed because of challenges linked to efficient delivery. Read more to find out about recent developments in oligonucleotide modifications, and the platforms that may be used to deliver them to target sites.

A pair of gloved hands arranging Eppendorf tubes on a rack in a laboratory setting. © Image by Belova59 from Pixabay

Oligonucleotide drugs have enormous potential to transform healthcare via the development of novel precision and/or personalized medicines for a plethora of unmet clinical needs. These include the neurodegeneration, rare diseases, cancers, viral infection, and disorders associated with ageing. Such oligonucleotide therapeutic modalities include gene silencing (e.g. by siRNA or gapmer oligonucleotides), modification of RNA processing (e.g. splice modulation using steric block oligonucleotides), gene activation, non-coding RNA inhibition, aptamers (which interact directly with a target protein), and genome editing using programmable nucleases (e.g. CRISPR-Cas9). Importantly, oligonucleotide-based therapeutics approaches are now reaching maturity, with ten drugs now approved by the US FDA. Many of these high-profile successes are limited to either local administration (e.g. to the eye or spinal cord) or delivery to liver after systemic injection. Indeed, the major hurdle to the development of oligonucleotide therapeutics is effective delivery of these molecules to their target tissues, cells, and sub-cellular sites of action. In the current issue of Nature Reviews Drug Discovery Dr Thomas Roberts and Professor Matthew Wood (from the Department of Paediatrics), together with Professor Robert Langer (MIT), discuss recent advances in oligonucleotide drugs delivery. This review provides an overview of oligonucleotide drug mechanisms of action and the plethora of chemical modifications which impart drug-like properties on these molecules. Established delivery strategies are discussed such as lipid nanoparticles and GalNAc bioconjugates (which both primarily target the liver), in addition to promising technologies being developed including exosomes, spherical nucleic acids, DNA nanostructures, and antibody conjugates.

Similar stories

New model for infant leukaemia announced

The breakthrough could lead to development of new treatments for infant Acute Lymphoblastic Leukaemia.

Changes in blood cell production over the human lifetime may hold clues to patterns of disease

A new paper published this week in Cell Reports reveals that changes in the gene expression of blood stem cells occur across the human lifetime; an important step in the understanding and treatment of blood disorders.

Promising discovery for treatment of neuromuscular diseases

Research led by Carlo Rinaldi and Catheryn Lim discovered that a naturally-occurring isoform of an androgen receptor can be used in therapy for spinal and bulbar muscular atrophy, and shows potential for other diseases.

New book highlights life-saving role vaccines play in prevention of killer diseases

'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

Why we must expand newborn screening

Early diagnosis is of primary importance both to obtain the best effect of innovative medications and to accelerate their development, writes Professor Laurent Servais.